{
  "docId": "019de074-48ca-708b-9817-9b094467f30f",
  "docSlug": "b3581031b12373a5077a05b88a8907f5",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 45,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a Kaplan-Meier survival curve and a study design flow chart.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-48ca-708b-9817-9b094467f30f/17",
  "deckHref": "/decks/019de074-48ca-708b-9817-9b094467f30f",
  "deckJsonHref": "/decks/019de074-48ca-708b-9817-9b094467f30f.json",
  "deckAnchorHref": "/decks/019de074-48ca-708b-9817-9b094467f30f#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.16,
        "y": 0.36
      },
      "kind": "chart",
      "text": "Overall survival Kaplan-Meier curve for CAPItello291",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c334cd37-88ba-469d-85d8-5f8e506852ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.56,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "CAMBRIA-1 trial design flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2924552b-1777-422c-8722-4b3935a1b368",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.16,
        "y": 0.68
      },
      "kind": "list",
      "text": "40% reduction in risk of disease progression or death; 50% reduction in biomarker altered population; US FDA Fast Track Designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb3e223d-078d-4846-b174-b75760f0bb72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.56,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "Phase II SERENA-2: PFS improvement over SoC at both 75mg and 150mg doses in ER+/HER2- patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8edefe42-7904-4b29-b480-0193d96e583f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "SABCS = San Antonio Breast Cancer Symposium; ngSERD = next-generation oral selective oestrogen receptor degrader; ...",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32502143-1922-4878-92e0-f2f011eab78f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Data-rich presence at SABCS, new adjuvant trial for camizestrant (ngSERD)",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aafd16b-09dd-415e-92d2-0e4ac525104c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology: R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5544975b-25a1-4418-bac7-cb8f1132bca9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "12af671d-7fdf-4235-952d-e888d472fda8",
      "evidence": "Structured bullet points for clinical trial outcomes",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "18107eda-4090-473e-bbf4-20d9925bf6b3",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck provides detailed information on financial results, oncology performance, and pipeline progress to satisfy the audience's need for information",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "6bc4b448-942a-484e-8a92-bc0a89369cb4",
      "evidence": "The deck presents a logical chain of information to support the company's growth prospects",
      "position": 0,
      "objective": "To demonstrate the company's growth potential",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}